CHICAGO -- November 19, 2026 -- Thirty-seven percent of surveyed U.S. households report that a member has used GLP-1 medications, up from 17% in 2024, according to a Circana report released Nov. 10. The share has risen about 2.2 times in two years, and 30% of households report a current user.
The report, titled GLP-1 Unlocked: The Next Phase of Consumer and Retail Transformation, tracks what these households buy after treatment begins. Its main finding is that the first year of treatment does not set the pattern for the second.
Restaurant spending index returns to within 0.5 points of its pre-treatment level in Year 2
Circana's Consumption Index compares average monthly spending by GLP-1 households with spending by non-user households in the same period. A reading of 100 means equal spending, and 121 means about 21% higher.
Households with a current GLP-1 user had a restaurant index of 121 before treatment. It fell 4.3 points in Year 1, to about 116.7 by our calculation. In Year 2 it recovered to within 0.5 points of the baseline, which puts it between roughly 120.5 and 121.5. GLP-1 households outspent non-user households in both years.
Retail food and beverage did not recover as fully. Its index stayed 1.9 points below the pre-treatment baseline in Year 2, although these households still spent more than non-users. For restaurants, the spending gap to non-user households has largely closed back to its pre-treatment size. At retail, it has not.
"The biggest misconception about GLP-1 consumers is that they will always buy less," said Sally Lyons Wyatt, Circana's global chief advisor.
Candy, frozen dessert, apparel and wearables indices all end Year 2 above baseline
The candy index passed its baseline in the second half of Year 1 and stood 5.7 points above it in Year 2. The frozen dessert index was 5.3 points above. Circana stresses that these are index-point changes relative to non-users, not percentage increases in actual spending.
Gains were larger outside food. The apparel index rose from 2.9 points above baseline in Year 1 to 6.4 points in Year 2, a gain of 3.5 points. The wearable and health technology index rose from 4.9 to 15.2 points above baseline, a gain of 10.3 points. That is about 3.1 times its Year 1 reading.
In the survey of households with a current user, 43% said they bought clothing or footwear because of GLP-1 use in the previous three months. Another 24% bought a health device or wearable, and 21% bought medication for side effects. For apparel and health-technology sellers, the data shows demand building in the second year rather than fading.
Circana projects GLP-1 households will buy 40% of US food and beverage units by 2030
If current adoption and spending trends continue, Circana projects that GLP-1 households could account for 40% of U.S. food and beverage units and 41% of non-food units by 2030. The projection assumes 35% to 40% of U.S. households will have an active user. Today 30% do, so the assumption implies a rise of 5 to 10 percentage points. At 35% household penetration, a 40% unit share would sit 5 points above the household share.
The household base is also not static. Among households with GLP-1 experience, 26% report two or more users, which works out to about 10% of all surveyed households (26% of 37%). The 7-point gap between households with any past or present user (37%) and those with a current user (30%) points to about 7% of households with former users only. Of surveyed previous-user households, 48% say they are at least somewhat likely to restart within a year. By our calculation that equals about 3.4% of all surveyed households, if the 7-point gap is the same group.
Circana compares active users with never-users using purchase data from August 2023 to July 2026
The analysis combines Circana's 2026 GLP-1 household survey with omnichannel household purchase data covering August 2023 through July 2026. Active users were identified in the July 2026 Receipt Panel survey and compared with households that had never used GLP-1 medications. Purchase data are aligned to each user's treatment start date. Circana did not disclose the survey sample size.
The pre-treatment baseline is the average index over the 12 months before treatment began. Circana describes consumer needs through a five-stage Consumer Reset Cycle: Adapt, Nourish, Renew, Sustain and Reconsider. The company says the stages may overlap or recur.